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Modelling mosquito infection at 
natural parasite densities identifies 
drugs targeting EF2, PI4K or ATP4 
as key candidates for interrupting 
malaria transmission
Koen J. Dechering1, Hans-Peter Duerr  2, Karin M. J. Koolen1, Geert-Jan van Gemert3, 
 Teun Bousema3, Jeremy Burrows4, Didier Leroy4 & Robert W. Sauerwein1,3
Eradication of malaria requires a novel type of drug that blocks transmission from the human to the 
mosquito host, but selection of such a drug is hampered by a lack of translational models. Experimental 
mosquito infections yield infection intensities that are substantially higher than observed in natural 
infections and, as a consequence, underestimate the drug effect on the proportion of mosquitoes that 
become infected. Here we introduce a novel experimental and computational method to adequately 
describe drug efficacy at natural parasite densities. Parameters of a beta-binomial infection model 
were established and validated using a large number of experimental mosquito infections at different 
parasite densities. Analyses of 15 experimental and marketed drugs revealed a class-specific ability to 
block parasite transmission. Our results highlight the parasite’s elongation factor EF2, PI4 kinase and 
the ATP4 sodium channel as key targets for interruption of transmission, and compounds DDD107498 
and KAE609 as most advanced drug candidates.
Since 2000, a global increase in the implementation of control measures has significantly decreased the burden 
of malaria1. With these successes in mind, global eradication seems feasible and the World Health Organization 
has put forward the vision of a world free of malaria with an intermediate milestone of 90% reduction in inci-
dence and mortality rates by 20302. This is a daunting task, as the disease currently continues to threaten half 
of the world’s population leading to 429,000 deaths annually3. A complicating factor is that current medication 
does not effectively clear the parasite stages that are infectious to the mosquito host, and patients cured from 
clinical disease may continue to transmit the pathogen for several weeks4. Achievement of the global eradication 
goal is critically dependent on the generation of novel intervention tools that target the transmission reservoir 
in the human and mosquito host5. The past decade has seen a renaissance in malaria drug discovery6,7. The gold 
standard for selection of transmission-blocking molecules from the emerging portfolio of candidate molecules 
is the Standard Membrane Feeding Assay (SMFA), where suspensions of cultured P. falciparum gametocytes are 
exposed to test compounds and fed to Anopheles mosquitoes. Approximately one week later the yield of infection 
is determined by counting the number of oocysts per infected mosquito (infection intensity) and the proportion 
of mosquitoes that carries at least one oocyst (infection prevalence)8,9. A drawback of the SMFA is that laboratory 
infections show 5 to 10-fold higher oocyst loads per mosquito than observed in natural infections, where parasite 
densities average at ~3 oocysts/midgut10–14. As a result, the effect on infection prevalence is underestimated15. For 
example, a drug that reduces the number of oocysts by 50% from 100 to 50 oocysts per midgut will hardly affect 
infection prevalence whereas an equivalent fractional reduction from 1 to 0.5 oocyst will significantly impact 
infection prevalence16,17. This problem that drug effects on infection prevalence are very sensitive to changes in 
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baseline infection intensity has been recognized before, and many studies have limited their analyses to reports 
on oocyst intensities14,15,18. There is an obvious divide between this outcome and the measure that is most relevant 
for public health, which is the reduction in the number of potentially infectious bites received by a person over a 
given time period. This Entomological Inoculation Rate is determined by the number of parasite-positive mos-
quitoes and their parasite loads19. Efficacy of a transmission-blocking drug would ultimately depend on reducing 
the proportion of infectious mosquitoes and the related force of infection experienced by the human popula-
tion16,17. It is, therefore, critical to evaluate candidate drugs for their ability to reduce infection prevalence at low 
infection intensities as observed in natural infections. In the present study, we set out to develop an experimental 
and computational strategy to assess compound effects on the infection prevalence at naturally occurring infec-
tion intensities. Our results show that infection prevalence can be robustly derived from modeling the infection 
intensity on basis of a beta binomial distribution of oocyst numbers. We have used this model to systematically 
evaluate the transmission-blocking effects of a set of mechanistically distinct antimalarials in preclinical and 
clinical development, and, for comparison, a set of marketed drugs.
Results
Dose-dependent reduction of oocyst intensities. A dataset was generated by testing the dose-de-
pendent effect of 15 different marketed and experimental antimalarial compounds in the SMFA. To this end, 
P. falciparum NF54 gametocytes were exposed to serial dilutions of compounds for 24 hours prior to feeding to 
Anopheles stephensi mosquitoes. The test compound remained present during feeding, mimicking a situation 
where a mosquito would feed on a gametocyte carrier with circulating drug levels. All compounds were tested 
at 9 different dilutions in duplicate. The baseline infection rate was determined by including 2 vehicle control 
feeders in every experimental run. Six to eight days post infection, mosquitoes were dissected to determine the 
oocyst intensities. Data for compounds DHA, KDU691, DDD107498 have been published in a different form pre-
viously, but were re-analyzed here8,20,21. A total of 8102 mosquitoes from 428 experimental feeds were analyzed. 
Parasite densities in the mosquito ranged from 0 to 126 oocysts per midgut, with a median of 9 and a mean of 13.8 
oocysts/midgut for mosquitoes from the control feeders.
The distribution of oocyst numbers in mosquitoes fed on a single feeder was modeled by a beta binomial 
distribution (BBD). The BBD model addresses the over-dispersion of oocyst intensities due to high numbers 
of uninfected mosquitoes. It is an alternative for negative binomial distribution models described previously 
but alleviates the need for zero-inflation strategies to explain the observed distribution of oocyst counts15,18. To 
describe dose-response relationships, mean oocyst intensities μ as a function of drug concentration c were fitted 
to a Hill function according to equation:
μ
μ
=
+ − −
c( )
1 10 (1)s pIC log c
0
( 50 ( ))intensity 10
whereby μ0 is the baseline mean infection intensity, pIC50intensity is the negative log of the concentration at the 
inflection point, and s is the Hill slope of the dose-response profile. Dispersion of oocyst distributions was 
parameterized by the variance to mean ratio (VMR), which describes the degree of over-dispersion of a distri-
bution and is a determinant of prevalence of infection (large VMRs indicate over-dispersed oocyst distributions 
of which the prevalence is lower compared to less over-dispersed distributions). Maximum Likelihood 
Estimation was used to find the best fit to the model parameters. Figure 1 shows the dispersion of oocyst counts 
and the fitted dose response curves. The data indicate that compounds DDD107498 and ELQ300 were most 
potent in reducing oocyst intensities, with pIC50intensity of 9.0 and 8.8, respectively. These potencies correspond 
with their activities against asexual blood stage parasites responsible for clinical malaria (Table 1). In contrast, 
compounds dihydroartemisin and artemisone from the class of endoperoxides, used as first line malaria treat-
ment, showed 100-fold lower potency in the SMFA than observed in asexual replication assays. Likewise, 
ACT451840, PA21A092, SJ55773, pyronaridine, ferroquine and lumefantrine showed relatively poor transmis-
sion blocking activity.
Drug effects on oocyst prevalence. Previous work has shown that the relative reduction in oocyst num-
bers is independent of the baseline infection intensity15,18. Thus, the pIC50 estimate on infection intensity will 
give similar results for experiments with high baseline infection intensities and experiments with much lower 
densities. In contrast, the relative reduction in oocyst prevalence, or the proportion of mosquitoes that carry at 
least one oocyst, is heavily dependent on the intensity of the infection. To further investigate this relationship we 
assessed the performance of the BBD model in estimating oocyst prevalence. The prevalence estimates obtained 
from modeling the intensity data showed an excellent correlation with observed prevalence in experimental feeds 
(R2 = 97%, Fig. 2). To further visualize the goodness-of-fit across the range of drug concentrations tested, the 
predicted prevalence values were plotted in the dose response plots in Fig. 1. The results show a near perfect fit 
with the experimentally determined prevalence data. To compare the experimental reduction in infection inten-
sity and oocyst prevalence, pIC50prevalence values were derived from the inflection points of the modeled preva-
lence curves. In general, the prevalence dose response curves show a right-shift in comparison to the intensity 
curves, and for all compounds the pIC50prevalence values were lower than the pIC50intensity values (Table 1). Notably, 
experiments with dihydroartemisinin and DDD107498 showed a large discrepancy between pIC50intensity and 
pIC50prevalence. This relates to the high baseline infection intensity and shallow Hill slopes of these compounds as 
will be explained below.
Prevalence as a function of intensity. Figures 1 and 2 indicate that infection prevalence is well pre-
dicted by the BBD model. The baseline infection intensity for these experiments was 13.8 oocysts/midgut on 
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average, which is much higher than generally observed in natural infections with 2–3 oocysts on average10–12. 
Therefore, we adapted the BBD model to simulate prevalence data at natural infection intensities. In keeping with 
previous reports22,23, we observed that the variance was proportional to the mean infection intensity (Fig. S1). 
Incorporating this function into the model allowed the simulation of compound efficacy at different infection 
intensities. The results of such simulations show that the efficacy in reducing infection prevalence increases with 
lower infection intensities, leading to an increase in the prevalence pIC50. This shift in pIC50 is more extreme 
with compounds that show low Hill coefficients (shallow curves). Figure 3A provides simulated examples for 
compounds DHA and KDU691 that showed shallow and steep Hill slopes, respectively. For DHA, the inflection 
point of the prevalence curve shifts 16-fold (pIC50 5.5 to 6.7) when baseline oocyst intensities drop from 100 to 
1 oocysts/midgut. In contrast, KDU691 is less sensitive to changes in parasite exposure and its inflection point 
shifts 2-fold (pIC50 6.2 to 6.5) when baseline oocyst intensities decrease from 100 to 1 oocysts/midgut. Figure 3B 
presents a more generalized description of these findings. It shows the simulated pIC50 of infection prevalence as 
a function of infection intensity for hypothetical compounds with pIC50intensity of 9, and Hill coefficients ranging 
from −0.5 to −4. The simulations show that an increase in infection intensity results in a decrease in prevalence 
pIC50. This effect is more pronounced with more shallow Hill slopes.
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Figure 1. Dose dependent reduction of infection intensity and infection prevalence. The figure shows oocyst 
intensities in individual mosquitoes from two independent feeds per drug concentration tested (open symbols). 
The left x-axis shows the infection intensity in the vehicle control feeders. The blue line shows the fit from the 
BBD model. The light blue dashed lines show the region of tolerance containing 95% of the observed oocyst 
intensities. The solid red symbols indicate the experimentally determined infection prevalence from the 
proportion of infected mosquitoes per feed. The solid red line indicates the infection prevalence predicted by 
the BBD model based on the fitted dispersion of oocysts.
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Next, we derived the function describing the data depicted in Fig. 3B by logistic regression using a least 
squares method to find the best fit (Fig. S2). The results showed that the pIC50 prevalence at any given infection 
intensity can be described by the following equation:
Compound
Target/
mechanism
baseline 
infection 
intensity 
(95% CI) VMR
Hill slope 
(95% CI)
pIC50 
intensity 
(95% CI)
pIC50 
prevalence 
(95% CI)
normalized 
pIC50 
prevalence, 
µ0=3
pIC50 
asexual 
asexual 
bloodstage
human  
dose (mg)
pCavg, 0–24 
hrs
ΔpIC50 
prevalence,µ0=3;pCavg
ΔpIC50asexuals; 
prevalence,µ0=3
ELQ300 BC1 / ATP production
31.82 (27.5; 
36.2) 14.50
−3.44 
(−4.5; 
−2.4)
8.81 (8.7; 
8.9)
8.58 (8.5; 
8.6) 8.69 8.32
33 −0.4
DDD107498
eEF2 
/ protein 
synthesis
37.08 (28.7; 
45.4) 14.80
−1.07 
(−1.3; 
−0.9)
9 (8.8; 
9.2)
8.12 (8.1; 
8.1) 8.63 9.00
20 0.4
KDU691
PI4K 
/ membrane 
trafficking
40.17 (37.6; 
42.7) 9.46
−4.05 
(−4.9; 
−3.2)
6.52 (6.5; 
6.6)
6.24 (6.2; 
6.3) 6.42 7.24
21 0.8
MMV390048
PI4K 
/ membrane 
trafficking
31.28 (28.9; 
33.6) 8.42
−2.42 
(−3.1; 
−1.7)
6.76 (6.7; 
6.9)
6.32 (6.3; 
6.3) 6.60 7.55
34 80(☥) 6.29 0.30 1.0
LMV599
PI4K 
/ membrane 
trafficking
3.21 (2.1; 
4.3) 4.75
−2.41 
(−3.4; 
−1.5)
7.79 (7.7; 
7.9)
7.81 (7.7; 
7.9) 7.62 8.72(*) 1.1
PA21A092
ATP4 
/ sodium 
homeostasis
12.4 (11.2; 
13.6) 2.29
−2.61 
(−3.3; 
−1.9)
6.83 (6.7; 
6.9)
6.57 (6.5; 
6.6) 6.68 8.30
35 1.6
SJ557733
ATP4 
/ sodium 
homeostasis
23.88 (21.4; 
26.3) 13.61
−1.99 
(−2.6; 
−1.4)
5.99 (5.8; 
6.1)
5.67 (5.6; 
5.7) 5.79 7.52
36 1.7
KAE609
ATP4 
/ sodium 
homeostasis
3.9 (3.2; 
4.6) 2.79
−2.22 
(−3; 
−1.5)
7.54 (7.4; 
7.7)
7.4 (7.3; 
7.5) 7.36 9.3
37 7529 6.00 1.35 1.9
ACT451840 PfMDR1 / transporter
28.53 (25.8; 
31.2) 12.17
−1.67 
(−2; 
−1.3)
7.57 (7.5; 
7.7)
7.06 (7; 
7.1) 7.33 9.40
38 2.1
OZ439 heme metabolism
3.01 (2.4; 
3.6) 2.40
−1.19 
(−1.5; 
−0.9)
6.89 (6.7; 
7.1)
6.78 (6.6; 
6.9) 6.55 8.72
39 80040 6.15 0.40 2.2
pyronaridine heme metabolism
9.03 (7.8; 
10.3) 6.85
−18.27 
(na;na) 6 (na; na)
5.98 (na; 
na) 5.98 8.31
25 18041 6.49 −0.51 2.3
DHA heme metabolism
19.26 (17.5; 
21) 4.07
−0.95 
(−1.1; 
−0.8)
7.03 (6.8; 
7.2) 5.98 (6; 6) 6.61 8.96
25 48042 6.91 −0.30 2.3
lumefantrine heme metabolism
5.99 (4.8; 
7.2) 3.69
−0.88 
(−1.4; 
−0.4)
6.37 (5.8; 
6.9)
5.96 (5.7; 
6.1) 5.92 8.55
25 96043 5.02 0.89 2.6
artemisone heme metabolism
5.55 (4.7; 
6.4) 3.23
−1.69 
(−2.2; 
−1.2)
6.68 (6.5; 
6.9)
6.47 (6.4; 
6.6) 6.45 9.10
25 2.6
ferroquine heme metabolism
18.93 (17.4; 
20.5) 8.09
−3.95 
(−5.2; 
−2.7)
6.07 (6; 
6.1)
5.87 (5.8; 
5.9) 5.97 8.72
44 2.8
Table 1. Overview of model estimates from experimental data. Columns list the following parameter estimates 
(for parameters see Methods, Statistical analyses): 1) Baseline infection intensity (μ0): average number of 
oocysts per mosquito midgut for the experiments analysed here. 2) VMR: variance to mean ratio as estimated 
by the BBD model. 3) Hill slope (s): slope of the Hill function. 4) pIC50intensity: IC50 of infection intensity. 5) 
pIC50prevalence: IC50 of oocyst prevalence (see Methods, logistic regression). 6) normalized pIC50prevalence, µ0=3: 
pIC50 for infection prevalence normalized on a baseline infection intensity of 3 oocysts per midgut according to 
formula (2), allowing for comparisons between compounds and experiments. In addition, the table lists pIC50 
values as reported for activity against the asexual blood stages. To compare pIC50prevalence values to human 
exposure data the table lists previously published plasma concentration as a pCavg (−log Cavg) for the first 
24 hours (pCavg,0–24hrs) following administration of the dose indicated in the column ‘human dose’. The column 
next to the pCavg values lists the difference between the normalized pIC50prevalence value and the pCavg value, to 
indicate the level of exposure above the transmission-blocking pIC50 value. Lastly, the table lists the difference 
between the asexual blood stage pIC50 and normalized pIC50prevalence. This value indicates the gap between the 
therapeutic and the transmission-blocking activity. The compounds are sorted from smallest to largest gap from 
top to bottom. CI: confidence interval. na: confidence interval not computed as the model did not fully converge 
at very steep Hill slopes. *Bryan Yeung, personal communication, ☥DL, unpublished data.
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where Sintensity relates to the experimentally derived Hill slope of the intensity dose response curve and µ0,target is 
the baseline infection intensity for which the IC50prevalence needs to be predicted. To evaluate whether this func-
tion accurately predicts experimental data, we plotted pIC50prevalence,pred calculated according to (2) against the 
pIC50prevalence values derived from the dose response curves depicted in Fig. 1. The results show an excellent cor-
relation between the fitted and calculated pIC50 values (Fig. 3C).
Drug efficacy at low infection intensities. Baseline oocyst intensities are known to vary greatly between 
individual SMFAs, even if highly standardized protocols are used8,14,15,24. In order to allow a comparison between 
data from different experiments we used formula (2) to calculate a normalized pIC50prevalence, µ0=3 where we used 
a baseline infection intensity of 3 as representative for natural infections. We subsequently ranked compounds 
according to the difference observed between the normalized prevalence pIC50 and the pIC50 as observed 
against asexual blood stages (Table 1). The larger the difference, the less likely a compound will reduce trans-
mission at concentrations that are relevant to its clinical efficacy in reducing asexual blood stage parasitemia. 
The resulting rank order deviates significantly from the order obtained by simply ranking compounds on basis 
of their asexual blood stage activity, and from the order obtained by ranking compounds on their pIC50intensity 
(Table S1). This indicates the importance of a proper assessment of transmission-blocking activity next to the 
determination of asexual blood stage activity. For a number of experimental antimalarials with available human 
pharmacokinetics data, we calculated the difference between the average plasma exposure in the first 24 hours 
after dosing (in -log M), and the pIC50prevalence. This value shows, on a log scale, the multiple of the IC50prevalence 
that on average is achieved following the anticipated human dose. For comparison, we included data for marketed 
compounds lumefantrine, dihydroartemisinin and pyronaridine. The latter two compounds showed a negative 
log difference between the average plasma concentration and the pIC50prevalence, indicating that the human expo-
sure does not reach levels that are likely to block transmission. For lumefantrine at a dose of 960 mg, the reported 
Cavg levels were 7.8-fold above the IC50prevalence. For the experimental antimalarials described here, OZ439 and 
MMV390048 showed a modest Cavg exposure above the IC50prevalence, with a multiple of 2.5 and 2.0 (log 0.4 and 
0.3), respectively. In contrast, KAE609 shows within the first 24 hours following a total dose of 75 mg average 
plasma concentrations that are 22-fold above the IC50prevalence. This indicates a clear potential for achieving block-
age of transmission at curative doses.
Discussion
Identification of the key pathways and candidate drugs for interrupting malaria transmission is essential to the 
implementation of strategies for malaria eradication. The methodology presented here provides a path for-
ward for triaging and prioritizing candidate drugs according to their ability to reduce mosquito infection rates. 
Modelling the distribution of oocyst numbers by means of a beta binomial distribution showed excellent proper-
ties with respect to model parameterization and goodness-of-fit. Dose response relationships could be described 
by a parsimonious model with only four parameters, the pIC50intensity, Hill slope, baseline infection intensity and 
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Figure 2. Validation of the model-predicted infection prevalence. The figure shows the correlation between 
observed prevalence and predicted prevalence for all experimental feeds. Identical colors indicate data from 
one dose response experiment. The red solid line indicates the regression line determined by linear regression 
using a least-squares method to find the best fit (R2 = 97%). The dashed blue lines indicate the 95% confidence 
intervals of the regression line.
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the VMR. This is in line with previous work that described the relationship between infection intensity and prev-
alence and highlighted that prevalence is determined by infection intensity and the degree of overdispersion of 
oocyst counts15,18. Our results indicate that VMR is a simple function of the infection intensity, and experimental 
data from high intensity infections may be used to predict infection outcomes at lower parasite exposures. Where 
inter-SMFA comparison of drug effects on infection prevalence was previously not feasible due to differences 
in baseline infection intensities, the introduction of a normalized pIC50 value resolves this issue and makes 
experimental data comparable. Using prevalence pIC50 values normalized to a baseline infection intensity of 3, 
which is in line with values observed in natural infections, we ranked 15 compounds from the global portfolio of 
marketed and experimental antimalarials according to magnitude of the gap between their asexual blood stage 
and transmission-blocking potency. The resulting rank order deviates from a rank order that would be based 
on pIC50prevalence values prior to normalisation, as for compounds like DHA and DDD107498 these values were 
severely underestimated as a result of the high baseline infection intensity in these experiments. Our ranked list 
reveals similar transmission-blocking properties of compounds that share the same mechanism of action. The 
results are in agreement with previous observations that compounds selected against the asexual blood stages 
in generally have a weaker activity against the transmission stages of the parasite13. The exception is provided by 
compound ELQ300 that showed a more potent transmission stage activity than asexual blood stage activity. Its 
mechanism of action depends on inhibition of the bc1 complex in the mitochondrial electron transport chain. 
This pathway is essential for replication of asexual blood stage parasites and sporogonic development in the mos-
quito, but dispensable for gametocyte maturation and gamete formation13,25. For a transmission-blocking drug, 
a sporontocidal mode of action limited to the mosquito stages of the parasites is less favoured than a gametocyt-
ocidal activity against parasites in the human host. Maturation of gametocytes takes around 10 days, and a drug 
that does not kill gametocytes but acts in the mosquito midgut to block onward parasite progression should have 
a very long circulating half-life in order to interrupt the cycle. In this respect, eEF2 inhibitor DDD107498 is a 
more attractive development candidate for reducing malaria transmission as its mode of inhibition of transmis-
sion depends on a gametocytocidal activity, combined with a weaker sporontocidal action20. Our data indicate it 
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Figure 3. (A) Simulated dose response curves for DHA and KDU691 at baseline oocyst intensities (µ0) of 1, 
10 and 100 oocysts/midgut. (B) relationship between the pIC50 of infection prevalence (pIC50prevalence) and 
the baseline infection intensity at different Hill slopes. Symbols indicate simulated data from the BBD model, 
the solid lines represent the results from a non-linear regression analysis using least squares to find the best fit. 
The simulations were run using a fixed value of 9 for the pIC50intensity parameter. The results indicate that the 
pIC50prevalence deviates from the pIC50intensity with increasing baseline infection intensities and shallower hill 
slopes. (C) correlation between observed and predicted pIC50 for infection prevalence. The figure compares 
the pIC50prevalence values derived by non-linear regression of the data presented in Fig. 1 to the predicted 
values (pIC50prevalence,pred) calculated according to formula (2). The blue solid line indicates the regression line 
determined by linear regression using a least-squares method to find the best fit (R2 = 96%), with the dashed 
blue lines indicating the 95% confidence interval. The dashed red line indicates the identity (y = x).
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is equipotent in reducing infection prevalence and inhibiting replication of asexual blood stage parasites. Indeed, 
at the minimum dose that fully cleared asexual blood stage parasites, it showed a 91% reduction in infection 
prevalence of mosquitoes fed on drug-treated mice20. These mice were infected with P. berghei parasites, result-
ing in an average infection intensity of 36.9 oocysts per midgut. At this parasite exposure, the experiment was 
likely to underestimate the efficacy on reducing prevalence for reasons described here. Further progression of 
DDD107498 as an antimalarial agent depends on the outcome of phase I safety studies, which are expected in 
the course of 2017. Further down the list of ranked compounds, PI4kinase inhibitors KDU691, LMV599 and 
MMV390048 all showed a 6 to 13-fold (log 0.8–1.1) difference between their asexual blood stage and transmis-
sion stage potencies. For ATP4 channel blockers PA21A092, KAE609 and SJ557733, this difference ranged from 
40 to 80-fold (log 1.6–1.9). The other compounds in our ranked list showed a greater than 100-fold difference 
between their asexual blood stage potency and transmission-blocking potency. Their potential application as a 
transmission-blocking drug seems unlikely, unless the gametocytocidal activity is driven by a short exposure to 
a peak concentration instead of a prolonged exposure to a lower concentration. In our SMFA experiments, par-
asites were exposed to drug for 24 hours. For a number of compounds that have human exposure data available, 
we compared the average 24-hour post-dosing exposure to the mosquito infection prevalence IC50, as a rough 
approximation to whether a transmission-blocking effect may be expected. For lumefantrine, that is used as part 
of artemisinin-based combination therapies (ACT), the Cavg0–24 is 7.8-fold (log 0.89) above the infection preva-
lence IC50, following a loading dose of 960 mg on the first day of treatment, This suggests that some reduction 
on transmission may be achieved. Few studies have investigated mosquito infection after treatment with malaria 
drugs. A study in the Gambia showed a greater effect of artemether/lumefantrine than of chloroquine plus sul-
fadoxine/pyrimethamine on parasite transmission of human gametocyte carriers to mosquitoes. Compared to 
other ACTs, artemether lumefantrine seems to exert the strongest transmission-reducing effect, suggesting that 
indeed the lumefantrine component contributes to a reduction in the number of infected mosquitoes26–28. The 
artemisinin component has weak effects on transmission, and our data indicate that DHA, used in combination 
with piperaquine, does not reach plasma exposure above the transmission-blocking IC50.
For the PI4K inhibitor MMV390048, human pharmacokinetic studies showed that average plasma levels in 
the 24 hours following a human dose of 80 mg are 2-fold above the IC50prevalence, µ0=3, which may lead to a partial 
reduction in parasite transmission in vivo. In spite of its lower transmission blocking potency, the profile of ATP4 
inhibitor KAE609 looks more attractive. Average plasma levels within 24 hours following a human dose of 75 mg 
are 22-fold above the IC50prevalence, µ0=3, with remaining plasma levels of approximately 600 nM after 24 hours29. 
Based on the characteristics of the dose response relationship described here, the 99% inhibitory concentration 
for reducing mosquito infection prevalence under natural infection intensities is estimated at 346 nM. Thus, a 
human dose of 75 mg is likely to lead to full sterilization of circulating gametocytes and blockage of mosquito 
infection.
Ultimately, prediction of a human effective dose depends on an understanding of the changes in in vivo drug 
levels in time and its effect on infectivity of the circulating gametocytes. This would benefit from a rodent trans-
mission model that would allow the determination of an in vivo ‘minimum sterilizing concentration’, in analogy 
with the mimimum parasiticidal concentration that is established for asexual blood-stage active drugs, where it 
defines the minimum in vivo concentration that achieves the maximum parasiticidal effect30. A rodent malaria 
transmission model has been proposed on basis of infection with P. berghei parasites31. Since this is a different 
species of Plasmodium its value for human malaria may be limited. Furthermore, oocyst intensities in mosqui-
toes infected through this model are very high (>40 on average) and the model will severely underpredict drug 
efficacy on infection prevalence for the reasons discussed here. Further development of promising molecules 
such as DD107498 would require a humanized rodent transmission model and, ultimately, a controlled human 
transmission model32.
Methods
Standard Membrane Feeding Assay. Standard Membrane Feeding Assays were performed as described 
previously8. Briefly, compounds were serially diluted in DMSO and subsequently in RPMI1640 medium supple-
mented with 10% human type A serum (Sanquin, The Netherlands). Diluted compounds were combined with 
P. falciparum NF54 stage V gametocytes and incubated for 24 hours at 37 °C in an Eppendorf tube. Following 
pre-incubation, parasites were pelleted by centrifugation and resuspended in human red blood cells in human 
type A serum to a hematocrit of 56%. Freshly diluted compound was added to the serum. The blood meal was fed 
to Anopheles stephensi mosquitoes using mini membrane feeders covered with a Parafilm membrane. Twenty-two 
feeders were used simultaneously, allowing analysis of nine compound dilutions and two positive (10 µM dihy-
droartemisinin) and two negative (0.1% DMSO) controls in a single experimental run. Non- and partially-fed 
mosquitoes were removed from the cages within 4 hours post feeding. Mosquitoes were maintained at 26 °C and 
70–80% humidity. Six to eight days later, midguts were dissected, stained with 1% mercurochrome and mounted 
on glass slides for microscopic examination of the number of oocysts per midgut (oocyst intensities). Oocyst 
prevalence was expressed as the percentage of mosquitoes from a single cage that carried at least one oocyst.
Statistical analyses. Oocyst counts were modelled by the beta binomial distribution (BBD) given by 
α β| = α β
α β
+ − +( )P k n nk( , , ) B k n kB( , )( , ) , whereby k is the number of oocysts in a mosquito, n is the maximum possi-
ble number of oocysts in a mosquito, and B(α,β) is the beta function. Based on historic experimental laboratory 
infection data, we assumed that maximally n = 300 oocysts can be found in a mosquito (observed maximum in the 
current dataset: n = 126). A sensitivity analysis based on n = 500 showed that estimates do almost not depend on n 
(results not shown). With = α
α β+
p  as the proportion of n oocysts, and dispersion parameter δ =
α β+ +
1
( 1)
, 
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expectation and variance of the BBD(n, α, β) are μ = np and σ δ= − + −np p n(1 )[1 ( 1)]2 . For purposes of 
biological interpretation we parameterize the BBD by p and δ= = − + −σ
μ
VMR p n(1 )[1 ( 1)]
2
, yielding BBD(n, 
p, VMR): δ| =
+ − − + − −
− − −
δ δ
δ δ
( ) ( )( )
( ) ( )
( ) ( )
P k n p nk( , , )
B k p n k p
B p p
1 , (1 ) 1
1 , (1 ) 1
1 1
1 1
, whereby δ = =
α β
−
− + +
−
n
1
1
1
( 1)
VMR
p(1 ) .
The mean oocyst number at a particular drug concentration, μ(c), was modeled by a Hill function of type 
=
+ −
p c( ) p
1 10 s log IC c
0
( 10( 50) )
, whereby c = log10(molar drug concentration), μ0 = p0 n is the baseline mean oocyst number 
for c = 0, s is the Hill slope and IC50 is the molar concentration at the inflection point of the Hill curve. The −log IC50 
is referred to as the pIC50intensity throughout the text. Parameter vector θ μ
→
= VMR IC s{ , , , ,}E 500  has been esti-
mated by Maximum Likelihood (ML) for each experiment E based on the BBD(n, p(c), VMR). The corresponding 
95% confidence intervals (CI) were derived from the corresponding Profile likelihood. The probability that mosqui-
toes do not have any oocysts is δ| = δ δ
δ δ
− + − −
− − −
P n p c c(0 , ( ), ( )) B p c c n p c c
B p c c p c c
( ( )(1/( ( )) 1), (1 ( ))(1/( ( )) 1))
( ( )(1/( ( )) 1), (1 ( ))(1/( ( )) 1))
; the proportion of 
infected mosquitoes is then δ= − |P c P n p c c( ) 1 (0 , ( ), ( )). Estimates and 95% CI for the pIC50prevalence have been 
derived from a constraint optimization given ML-estimates θ μ→ = ˆ ˆ ˆVMR IC s{ , , , ,}E 0 50  and their 95% CI. Since the 
proportion of infected mosquitoes is not a model parameter, but a model outcome, corresponding estimates were 
derived at the limits of the Profile likelihood of θˆE.
In order to simulate low parasite exposure data from high intensity experiments, and vice versa, the baseline 
VMR was approximated by σ = + μ −( )Log a s( ) Log b10
2 ( )10  as shown in Figure S1. Resulting estimates were 
a = −12.95 and b = −25.91 and s = 1.105. The baseline VMR is then given by σ μ=VMR /0
2
0 0.
Using the BBD model and above VMR0 estimate, infection prevalence pIC50 values were simulated for a range 
of baseline oocyst intensities from 0–100 and Hill slopes from −0.5–5.0 for a hypothetical compound with an 
pIC50 on infection intensity of 9. The simulated pIC50prevalence decreased linearly with the Log-transformed base-
line mean infection intensity and was fitted by = + + + µpIC pIC a s b b s log50 50 / ( / ) ( )prevalence pred intensity, 1 1 2 10 0 . 
Least squares estimation suggested b1 as not significantly different from zero, so that the model could be reduced 
to = + + µpIC pIC50 50prevalence pred intensity
a b log
s,
( )1 2 10 0 . Estimates (95% CI) from logistic regression were, a1 = 0.114 
(0.090–0.138), and b2= 0.595 (0.580–0.610).
Compound effects on parasite transmission were compared to previously reported activities against asexual 
blood stage parasites. To this end, the −logIC50 (pIC50) was derived from IC50 values previously published 
as listed in Table 1. To compare pIC50prevalence to circulating drug levels of humans exposed to MMV390048, 
KAE609, OZ439, pyronaridine, dihydroartemisinin or lumefantrine, average drug levels were calculated based 
on published data and dosages indicated in Table 1. To this end, the published area under the curve values for the 
first 24 hours following the first dose were divided by 24 to give the average concentration Cavg. This value was log 
transformed and the sign was inverted to yield a pCavg.
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